[HTML][HTML] Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS

GJ Korpanty, DM Graham, MD Vincent… - Frontiers in …, 2014 - frontiersin.org
Lung cancer remains the most lethal malignancy in the world. Despite improvements in
surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients …

Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype

S Rodic, MD Vincent - International journal of cancer, 2018 - Wiley Online Library
Cancer cells exhibit a wide range of metabolic phenotypes, ranging from strict aerobic glycolysis
to increased mitochondrial respiration. The cause and utility of this metabolic variation …

Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model

CH Lineweaver, PCW Davies, MD Vincent - BioEssays, 2014 - Wiley Online Library
In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a
reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are …

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

…, N Davidson, P Harper, MD Vincent… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: This phase III study was designed to demonstrate equivalence in survival of oral
uracil/tegafur (UFT) and oral leucovorin (LV) to conventional intravenous (IV) fluorouracil (5-…

Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival

…, AT Tomiak, PT Truong, MD Vincent… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To determine the impact of continued smoking by patients receiving chemotherapy
(CHT) and radiotherapy (RT) for limited-stage small-cell lung cancer (LSCLC) on toxicity …

[PDF][PDF] Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non–small-cell lung cancer: NCIC Clinical …

…, D Walde, F Laberge, MD Vincent… - Journal of clinical …, 2010 - researchgate.net
Vincent, Peter M. Ellis, Scott A. Laurie, Keyue Ding, Eliot Frymire, Isabelle Gauthier, Natasha
B. … Vincent, AstraZeneca (C); Christopher W. Lee, AstraZeneca (C) Stock Ownership …

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on …

…, B Samson, A Shah, MP Thirlwell, MD Vincent… - Current …, 2007 - mdpi.com
Chemotherapy-induced diarrhea (cid) is a common side effect of cancer treatment and can
cause significant morbidity and mortality. Diarrhea is frequently severe enough to require a …

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

…, TJ George, I Garrido-Laguna, AL Coveler, MD Vincent… - 2022 - ascopubs.org
360490 Background: KRAS mutation is present in 90% of pancreatic ductal adenocarcinomas
with p.G12C accounting for 1% to 2% of these mutations. Sotorasib, a small molecule that …

ICP-OES and ICP-MS for the determination of metals: application to oysters

J Sneddon, MD Vincent - Analytical Letters, 2008 - Taylor & Francis
This mini-review gives a general overview of inductively coupled plasma-optical emission
spectrometry (ICP-OES) and inductively coupled plasma-mass spectrometry (ICP-MS) for the …

Cancer: beyond speciation

MD Vincent - Advances in cancer research, 2011 - Elsevier
… I will also draw on a third essay (Vincent, in preparation). These essays deal with unorthodox
conceptualizations of the malignant condition, and the therapeutic implications of these …